Bavarian Nordic opjusterer sine økonomiske forventninger til 2024
26 sept. 2024 10h30 HE
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 26. september 2024 – Bavarian Nordic A/S (OMX: BAVA) opjusterer sine økonomiske forventninger til 2024. På baggrund af den i dag offentliggjorte ordre på selskabets mpox-vaccine...
Bavarian Nordic Upgrades its Financial Guidance for 2024
26 sept. 2024 10h30 HE
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured,...
Bavarian Nordic indgår aftale med UNICEF om levering af 1 million doser mpox-vaccine
26 sept. 2024 10h30 HE
|
Bavarian Nordic A/S
Første tildeling under UNICEF’s nødudbud, der skal sikre tilgængelighed af mpox-vacciner til Afrika KØBENHAVN, Danmark, 26. september 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag...
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
26 sept. 2024 10h30 HE
|
Bavarian Nordic A/S
First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement...
Bavarian Nordic modtager USD 63 mio. fra den amerikanske regering for produktion og levering af yderligere koppe- og mpoxvacciner
24 sept. 2024 11h30 HE
|
Bavarian Nordic A/S
Kontrakten vil øge lageret af råvaccine samt sikre leverancer af yderligere frysetørrede vaccinerLeverancer er planlagt i 2025 og senere KØBENHAVN, Danmark, 24. september 2024 – Bavarian Nordic A/S...
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines
24 sept. 2024 11h30 HE
|
Bavarian Nordic A/S
Contract will further strengthen the U.S, bulk vaccine inventory and secure additional freeze-dried dosesDeliveries planned for 2025 and beyond COPENHAGEN, Denmark, September 24, 2024 – Bavarian...
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
19 sept. 2024 09h45 HE
|
Bavarian Nordic A/S
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger...
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
19 sept. 2024 09h45 HE
|
Bavarian Nordic A/S
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger...
Gavi indgår aftale med Bavarian Nordic for at sikre hurtig levering af 500.000 doser mpox-vaccine til Afrika
18 sept. 2024 04h45 HE
|
Bavarian Nordic A/S
Forhåndskøbsaftalen vil blive finansieret af Gavi’s First Response Fund, som blev etableret efter COVID-19-pandemien med henblik på at sikre hurtig adgang til knappe vaccineforsyninger i fremtidige...
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
18 sept. 2024 04h45 HE
|
Bavarian Nordic A/S
The advance purchase agreement (APA) will be funded by Gavi’s First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health...